BioPharmSignal logoBioPharmSignal

Biotech News

Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference

Innate Pharma (IPHA)Innate PharmaConference / presentation

Thu, 07/23/2026 - 07:00

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma, will participate in the panel discussion, Changing Treatment Landscape in Bladder Cancer, at the BTIG Virtual Biotechnology Conference.

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer

Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

Related news

IPHAInnate Pharma2026-08-14 08:26 EST

Innate Pharma announces conference call and webcast

IPHAInnate Pharma2026-07-20 14:53 EST

Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

View all latest news

Innate Pharma

Innate Immunity Oncology Company Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer. Lacutamab Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma. ADC and Partnered Pipeline IPH4502 is a Nectin-4 ADC, while partnered programs include...

Recent company news

IPHAInnate Pharma2026-08-14 08:26 EST

Innate Pharma announces conference call and webcast

IPHAInnate Pharma2026-08-13 07:14 EST

Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares

IPHAInnate Pharma2026-08-10 14:02 EST

Innate Pharma Announces Proposed Offering of Ordinary Shares

IPHAInnate Pharma2026-08-09 21:32 EST

Innate Pharma to advance Lacutamab towards phase 3 following partnership with Sobi and appoints new chief medical officer

IPHAInnate Pharma2026-08-09 20:37 EST

Innate Pharma enters strategic partnership with Sobi to license lacutamab in T-cell lymphoma

Stock data

Close
2.26 USD
Market cap
170.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States